Verici Dx reports a 53 per cent increase in testing revenue for the first half of 2026 from Tutivia, its kidney-transplant test, with thirty-five United States transplant centres now using it and further expansion expected — company-reported figures, presented here with the attribution they require, that nevertheless mark a real commercial milestone for transplant diagnostics.
The company is raising approximately eight million pounds through a placing and retail offer to fund commercial-team expansion, marketing, laboratory investment and working capital, targeting 4.75 million dollars of Tutivia revenue for 2026. That sequence — clinical adoption first, salesforce second, guided by a revenue target the market can grade — is the standard biography of a diagnostic leaving its validation phase, and it exposes the company to the standard test: whether ordering clinicians renew and expand use once the early-adopter centres have reported their experience.
Transplant medicine explains the demand. Kidney recipients live under lifelong surveillance for rejection, historically anchored in biopsies and imperfect blood markers; a test that helps clinicians judge graft health less invasively addresses a genuine clinical anxiety, which is why centre adoption — thirty-five and counting — is the figure nephrologists will weigh more heavily than any revenue percentage. Company claims about performance still rest on the published validation behind the test, and this desk does not present commercial growth as clinical proof.
The financing deserves the same two-handed reading. Eight million pounds buys the commercial build-out the plan requires and dilutes existing holders; it is growth capital raised from a position of reported momentum rather than distress. Whether it was raised at the right price, and whether the 4.75-million-dollar target is beaten or walked back, will be known from the company’s own reports across the next two quarters.
For morning readers, Tutivia’s half-year is a clean case study in how diagnostics actually spread: not by breakthrough headlines but centre by centre, clinician by clinician, claim by reimbursed claim. Fifty-three per cent growth on a small base is easy to dismiss and easy to over-read. The adoption count is the number to keep.
Transplant centres are conservative adopters for good reason — a wrong signal can cost a graft — so each addition to the thirty-five carries more evidential weight than a hundred consumer downloads. If that count keeps climbing through the funded commercial push, the revenue target will take care of itself; if it stalls, no salesforce arithmetic will rescue it.
